Varespladib Alleviates Colonic Inflammation Induced by High‐Fat Diet via Downregulating the TGF‐β/Smad Pathway and AA Pathway by Inhibiting sPLA 2
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.70130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Meng Shirui und 6 weiteren Autor:innen. Beteiligte Einrichtung: Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Diet, High-Fat, Transforming Growth Factor beta, Signal Transduction, Smad Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangxi Province, Foundation for Innovative Research Groups of the National Natural Science Foundation of China, Research Project of Jiangxi Provincial Department of Education.
Abstract (Originalsprache)
Background and Aim High‐fat diets (HFD) increase the risk of colonic inflammation. Varespladib, an sPLA 2 inhibitor, has shown potential to treat a variety of inflammatory diseases. Its role in colonic inflammation caused by a HFD remains to be studied.
Methods
C57/BL6 mice were fed a chow diet (NCD), HFD, or HFD with varespladib for 4 weeks. Various parameters were measured to assess the effects of varespladib on HFD‐induced metabolic changes. The TGF‐β/Smad and the arachidonic acid pathway were analyzed using RT‐qPCR and western blotting.
Results
Varespladib supplementation in HFD‐fed mice led to reduced body weight and abdominal adiposity, improved intestinal health and blood lipid profiles, mitigated intestinal inflammation and fibrosis, downregulated genes associated with immunity and permeability, and inhibited key inflammatory pathways.
Conclusion
Short‐term HFD induced intestinal inflammation. These disorders are mainly triggered by sPLA 2 upregulation, resulting in activation of the arachidonic acid and TGF‐β/smad pathways. Varespladib has significant therapeutic potential for alleviating HFD‐induced colonic inflammation in mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang, China.
- School of Basic Medicine Sciences, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of General Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
ORCID-Profile: Wang Linfeng
Förderung
- Natural Science Foundation of Jiangxi Province
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- Research Project of Jiangxi Provincial Department of Education
- National Natural Science Foundation of China
Zitieren
APA
Shirui, M., Yuanyuan, L., Linfeng, W., Jiahao, L., Daixuan, Z., Ying, X., & Chunhong, H. (2025). Varespladib Alleviates Colonic Inflammation Induced by High‐Fat Diet via Downregulating the TGF‐β/Smad Pathway and AA Pathway by Inhibiting sPLA 2. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70130
Vancouver
Shirui M, Yuanyuan L, Linfeng W, Jiahao L, Daixuan Z, Ying X, et al. Varespladib Alleviates Colonic Inflammation Induced by High‐Fat Diet via Downregulating the TGF‐β/Smad Pathway and AA Pathway by Inhibiting sPLA 2. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.70130
BibTeX
@article{Shirui2025,
author = {Shirui, Meng and Yuanyuan, Li and Linfeng, Wang and Jiahao, Liu and Daixuan, Zhou and Ying, Xiong and Chunhong, Huang},
title = {Varespladib Alleviates Colonic Inflammation Induced by High‐Fat Diet via Downregulating the TGF‐β/Smad Pathway and AA Pathway by Inhibiting sPLA 2},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.70130}
}
EUVIMED